TNGX
Tango Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$23.53
+6.76%Year over year
Reported trailing growth
- Revenue
- +121.5%
- EBITDA
- +18.7%
- EBIT
- +13.3%
- EPS
- +35.6%
- Free cash flow
- +3.3%
- Operating cash flow
- +2.9%
Forward estimates
Based on analyst estimates
- Revenue
- -91.5%
- EBITDA
- -93.3%
- EPS
- -86.1%
Three-year CAGR
- Revenue
- +35.9%
- EBITDA
- +22.2%
- EBIT
- +23.6%
- Net income
- +22.0%
- EPS
- +26.9%
- Free cash flow
- -5.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026